NEUROSTEMCELL

European Consortium for Stem Cell Therapy for Neurodegenerative Diseases

 Partecipanti

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The NEuroStemCell consortium will foster collaboration between leading European experimental and clinical researchers in order to maximise the prospects for successful clinical trials of stem cell therapy for Parkinson's (PD) and Huntington's (HD) Disease. The activities will be driven by a Clinical WorkPackage (WP), which will set the requirements, and monitor and guide advances in development of the most promising cells. The goal is to compare different stem cell sources with respect to their capcity to generate mesencephalic Dopaminergic and striatal GABAergic neurons suitable for neuronal cell replacement. The major sources will be neuralised Embryonic Stem (ES) cells, adherent Neural Stem (NS) cell lines and short term expanded Ventral Midbrain neural stem cells/progenitors grown as Neurospheres (VMN). Two exploratory WPs will use extrinsic cues to specify neuronal differentiation and compare rigorously the different human stem cell lines and their progeny in giving rise to authentic neurons. WP3 will integrate long-term assessements of functional (motor and cognitive) recovery in appropriate animal models of PD and HD, and WP4 will exploit non-invasive in vivo imaging to evaluate the survival, composition, integration and functional impact of the donor cells in host brain. These two WPs will also provide the elements necessary to standardise the extent of recovery as a function of cell replacement and integration. In WP5, three SMEs will generate the technologies for manufacturing and scale-up of safe, fully traceable, efficacious and banked stocks of cells ready for clinical use. Regulatory and ethical requirements will be considered in the Clinical WP which also incorporates training. Building on the successful experience of the FPVI EuroStemCell project, NEuroStemCell will provide a focal point for European researchers engaged in the translational aspects of stem cell-based strategies to develop cures for PD and HD'

Introduzione (Teaser)

Stem cell technology holds great promise for clinically treating various diseases. EU researchers tested how stem cell differentiation into functional neuronal cells could be exploited as a therapeutic intervention for neurodegenerative disorders.

Descrizione progetto (Article)

Neurodegenerative disorders such as Parkinson's disease (PD) and Huntington's disease (HD) are characterised by the progressive loss of specific types of neurons. Their increasing prevalence poses a heavy socioeconomic burden across Europe.

Currently available pharmacological treatment is only palliative in nature and of little help to such patients. These degenerative diseases are therefore ideal candidates for replacement stem cell-based therapies where the damaged neurons are substituted by new functional cells. The EU-funded 'European consortium for stem cell therapy for neurodegenerative diseases' (http://www.neurostemcell.org/ (NEUROSTEMCELL)) consortium aimed to develop stem cell therapies for neurodegenerative disorders all the way to the clinic. The project brought together research and clinical expertise in the field to develop validated cells and clinical grade reagents for clinical trials.

Key activities of the NEUROSTEMCELL project included the establishment of protocols for generating GABAergic and dopaminergic neuronal cells from stem cells suitable for clinical transplantation. For this purpose they used embryonic and fetal stem cells as well as induced pluripotent stem cells, and tested their in vivo performance following transplantation.

The regenerative efficacy of the approach was evaluated in preclinical models of PD and HD using MR and PET imaging techniques. In particular, the stem-cell derived dopaminergic neurons not only survived the transplantation process, but matured into the desired neuronal type and induced significant recovery of motor behaviour.

To comply with clinical specifications, partners had to optimise GMP manufacturing conditions and up-scaling protocols for the generation of clinical grade cells. They also investigated all the steps required for translating a research protocol to the clinic from a scientific, clinical, regulatory and ethical point of view.

On its completion, the NEUROSTEMCELL study has provided significant knowledge on the mechanisms of stem cell differentiation and specification towards specific neuronal fates. Significant progress has been achieved towards the potential of stem cell therapy for treating neurodegenerative disorders and restoring neuronal function in millions of patients worldwide.